Breaking Health News: Major Drug Approvals and Controversies

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese patients, the US FDA's approval of treatments for a rare genetic disorder and multiple myeloma, and a legal challenge to drug price negotiations. There are updates on insulin pricing lawsuits, novel flu vaccines, and advances in reproductive therapy.

The European Medicines Agency has endorsed the use of Novo Nordisk's drug Wegovy to alleviate heart failure among obese patients, marking the drug's second endorsement for health benefits beyond weight loss, as announced by the Danish pharmaceutical company on Thursday.

In the United States, the FDA granted approval for Zevra Therapeutics' treatment for a rare genetic disorder, making it the first sanctioned therapeutic for the condition after multiple review extensions. Additionally, the FTC has launched a lawsuit against major pharmacy benefit managers for capitalizing on higher insulin prices.

Meanwhile, Sanofi's recent trials reveal promising results for its multiple sclerosis drug candidate tolebrutinib, which delays disease progression by 31%. This comes alongside significant developments in self-administered flu vaccines and innovative steps forward in in-vitro fertilization (IVF) and jaundice prevention.

(With inputs from agencies.)